Exhibit 99.1

FORWARD LOOKING STATEMENTS © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Ce rt ain st a t emen ts in t hi s pr e s en t a t ion ma y con st i tut e “ fo rw a r d - looking st a t emen ts ” w i t hin t he meaning of t he P r i v a t e Sec ur i t ie s Li t iga t ion Refo r m Ac t of 1995. All st a t emen ts , o t he r t han st a t emen ts of hi st o r ical fac t , con t ained he r ein a r e fo rw a r d - looking st a t emen ts. Fo rw a r d - looking st a t emen ts in v ol v e kno w n and u nkno w n r i s k s , u nce rt ain t ie s , and o t he r fac t o rs t ha t ma y ca us e ac tu al r e su l ts t o diffe r ma t e r iall y f r om t ho s e e xpr e ss ed o r im p lied in su ch st a t emen ts. Fo r a di s c uss ion of t he s e r i s k s and u nce rt ain t ie s , r efe r t o Gel t e q ’ s filing s w i t h t he U . S . Sec ur i t ie s and E x change Commi ss ion (“ SEC ”), incl u ding i ts Ann u al Re p o rt on Fo r m 20 - F filed on No v embe r 17 , 2025. Gel t e q u nde rt ake s no obliga t ion t o up da t e an y fo rw a r d - looking st a t emen ts t o r eflec t e v en ts o r ci r c u m st ance s af t e r t he da t e he r eof .

A global clinical and s cience ba s ed com p an y t ha t ha s de v elo p ed a no v el d ru g deli v e ry p la t fo r m in an inge st ible gel fo r m Gel t e q sp eciali z e s in t he fo r m u la t ion , de v elo p men t and man u fac tur ing of gel pr od u c ts fo r licen s ed p a rt ne rs Fo u nded in 2017 in Melbo ur ne , A ustr alia , t he com p an y eme r ged f r om i ts fo u nde rs ’ w o r k a s a die t i t ian , aiming t o im pr o v e p a t ien t com p liance w i t h an ea sy t o sw allo w and enjo y able deli v e ry fo r ma t fo r medica t ion s and n utr i t ional supp lemen ts © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. GELTEQ ( NASDAQ : GELS ) OVERVIEW

GELTEQ - COMPANY HIGHLIGHTS Inno v a t i v e d ru g and n utr ien t deli v e ry p la t fo r m t ha t i s ma r ke t r ead y Po rt folio of n utr ace ut ical pr od u c ts al r ead y de v elo p ed and s ale s r ead y Gel t e q hold s m u l t i p le p a t en t familie s t ha t co v e r a r ange of a pp lica t ion s fo r o ur pr o pr ie t a ry gel t echnolog y Pilo t n utr ace ut ical o r de rs r ecen t l y deli v e r ed in China , USA and A ustr alia Di v e rs e API p i p eline a v ailable fo r R & D and licen s ing p a rt ne rs hi ps © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

RESEARCH AND VALIDATION PARTNER Engaged Mona s h Uni v e rs i ty ’ s Medicine s Man u fac tur ing Inno v a t ion Cen tr e ( MMIC ) t o bo t h v e r if y and t e st o ur s cien t ifc me t hodologie s. Mona s h Uni v e rs i ty i s a global leade r in Pha r mace ut ical Science # 4 Pha r mac y and Pha r macolog y QS Ranking s 2025 ( Global )* Gel t e q ’ s s cien t i st t eam i s ba s ed in Mona s h Inno v a t ion Lab s w hich i s a g r o wt h and de v elo p men t eco syst em w i t hin Mona s h Uni v e rs i ty. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. * h ttps :// www.t o pu ni v e rs i t ie s. com / u ni v e rs i ty - su bjec t - r anking s / p ha r mac y - p ha r macolog y

To im pr o v e t he li v e s of h u man s and animal s b y making d ru g and n utr ace ut ical pr od u c ts mo r e acce ss ible and ea s ie r t o con su me © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. MISSION STATEMENT

INDUSTRY CHALLENGES Pa t en t lifec y cle pr e ssur e s a s d ru g p a t en ts e xp i r e B r inging a 90% r e v en u e d r o p w hen gene r ic s a rr i v e ** Pill A v e rs ion and S w allo w ing i ssu e s ~40% of con su me rs stru ggle w i t h sw allo w ing supp lemen ts* Con v enience Con su me rs a r e demanding ne w, no v el and con v enien t fo r ma ts Poo r adhe r ence Lo w medica t ion adhe r ence mean s le ss in t ake and p oo r e r heal t h o ut come s C r o w ded ma r ke ts W i t h limi t ed o pt ion s fo r diffe r en t ia t ed deli v e ry fo r ma ts Inabili ty t o hold la r ge do s age s A v ailable e x i st ing fo r ma ts su ch a s g u mmie s, p ill s and ca psu le s can ’t hold la r ge do s age s * McClo s ke y , A . P . , Pen s on , P . E . , T s e , Y . , Abdelhafi z , M . A . , Ahmed , S . N . and Lim , E . J . , 2022. Iden t if y ing and add r e ss ing p ill a v e rs ion in ad u l ts w i t ho ut p h ys iological - r ela t ed d ysp hagia : A na rr a t i v e r e v ie w. B r i t i s h Jo ur nal of Clinical Pha r macolog y , 88 ( 12 ), pp.5128 - 5148. ** R u mo r e , M . M . and Vogenbe r g , F . R . , 2016. Bio s imila rs : st ill no t qu i t e r ead y fo r pr ime t ime . Pha r mac y and The r a p e ut ic s , 41 ( 6 ), p.366. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Challenge s t ha t p ha r mace ut ical & supp lemen t com p anie s a r e facing

The o r al deli v e ry of oil - s ol u ble ( li p o p hilic ) o r in s ol u ble com p o u nd s a r e a majo r challenge fo r p ha r mace ut ical com p anie s. 40 – 60 % of ma r ke t ed d ru g s and up t o 90 % of di s co v e ry candida t e s a r e p oo r l y s ol u ble * Pha r mace ut ical com p anie s a r e al r ead y in v e st ing ~ USD $ 4 - 7 Bn ann u all y in t echnologie s t ha t im pr o v e deli v e ry of p oo r l y s ol u ble / oil y d ru g s ** INDUSTRY CHALLENGES * Xie , B . , Li u , Y . , Li , X . , Yang , P . and He , W . , 2024. Sol u bili z a t ion t echni qu e s us ed fo r p oo r l y w a t e r - s ol u ble d ru g s. Ac t a Pha r mace ut ica Sinica B , 14 ( 11 ), pp.4683 - 4716. ** Sol u bili ty Enhancemen t E x ci p ien ts Ma r ke t Si z e 2025 - 2032 h ttps :// s ha r e . google / DUYk 0 RWZb 7 Z 9 m u U 3 g © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

Imagine if t he r e w a s an inno v a t i v e deli v e ry p la t fo r m t ha t co u ld add r e ss t he challenge s t ha t p ha r mace ut ical and n utr ace ut ical com p anie s a r e e xp e r iencing © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. IMAGINE

THE GELTEQ SOLUTION © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q ’ s p a t en t ed gel deli v e ry can p o t en t iall y syst em s ol v e man y of t he p ha r mace ut ical and supp lemen t ind ustry ’ s challenge s - f r om p oo r adhe r ence and p ill fa t ig u e t o t he o r al deli v e ry of in s ol u ble ing r edien ts O ur gel s can incl u de s ingle o r m u l t i p le w a t e r s ol u ble , fine in s ol u ble and oil - s ol u ble ing r edien ts Thi s can incl u de v i t amin s , mic r o and mac r o n utr ien ts , he r bal e xtr ac ts and ac t i v e p ha r mace ut ical ing r edien ts ( API s ), in a s ingle s helf - st able gel w i t h a u nifo r m t e xtur e and com p o s i t ion

T r ial r e su l ts s ho w ed Gel t e q ’ s inno v a t i v e t echnolog y fo r w a t e r s ol u ble com p o u nd s w a s able t o : Im pr o v e bioa v ailabili ty ( o v e r all ab s o rpt ion ) b y o v e r 40 % . P r o v ide fa st e r ab s o rpt ion fo r an API Enhance ing r edien t ab s o rpt ion w hich can deli v e r s ignifican t l y im pr o v ed effec t i v ene ss of t he d ru g Inc r ea s e p eak concen tr a t ion s The demon str a t ed bioa v ailabili ty enhancemen ts b y a s ignifican t ma r gin pr o v ide s a str ong fo u nda t ion fo r a pp l y ing Gel t e q ’ s p la t fo r m ac r o ss m u l t i p le o t he r w a t e r - s ol u ble d ru g cla ss e s , w i t h t he p o t en t ial t o e xp and t he Com p an y ’ s comme r cial s co p e Graph = Gelteq trial results with a water soluble drug and FDA approved product GELTEQ ADVANTAGES - WATER SOLUBLE COMPOUNDS Plasma concentration Water soluble drug in Gelteq gel Water soluble drug with water time post - administration (hours) © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

GELTEQ ADVANTAGES - OIL SOLUBLE COMPOUNDS time post - administration (hours) Graph = Gelteq trial results with an oil soluble drug and FDA approved product T r ial r e su l ts s ho w ed Gel t e q ’ s inno v a t i v e t echnolog y fo r oil s ol u ble com p o u nd s w a s able t o : Ha v e 300 % fa st e r ab s o rpt ion of an API in t he fi rst ho ur w hich can can deli v e r s ignifican t l y im pr o v ed efficienc y of t he d ru g Im pr o v e bioa v ailabili ty ( o v e r all ab s o rpt ion ) b y o v e r 20 % . Inc r ea s e p eak concen tr a t ion s The enhanced bioa v ailabili ty and sp eed of ab s o rpt ion pr o v ide s a str ong fo u nda t ion fo r a pp l y ing Gel t e q ’ s p la t fo r m ac r o ss m u l t i p le o t he r oil - s ol u ble d ru g cla ss e s and add r e ss ing a ke y ind ustry need Plasma concentration Oil soluble drug in Gelteq gel Oil soluble drug © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

GELTEQ IS REIMAGINING THE ADMINISTERED DOSE © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q pr od u c ts can be deli v e r ed in a w ell e st abli s hed p ackaging fo r ma t t ha t i s w ell ado pt ed in t he ma r ke t... d r i v en b y con v enience VS

GELTEQ CAN SOLVE INDUSTRY CHALLENGES © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Pa t en t lifec y cle pr e ssur e s a s d ru g p a t en ts e xp i r e Pill A v e rs ion and S w allo w ing i ssu e s Con v enience Poo r adhe r ence C r o w ded ma r ke ts Inabili ty t o hold la r ge do s age s * McClo s ke y , A . P . , Pen s on , P . E . , T s e , Y . , Abdelhafi z , M . A . , Ahmed , S . N . and Lim , E . J . , 2022. Iden t if y ing and add r e ss ing p ill a v e rs ion in ad u l ts w i t ho ut p h ys iological - r ela t ed d ysp hagia : A na rr a t i v e r e v ie w. B r i t i s h Jo ur nal of Clinical Pha r macolog y , 88 ( 12 ), pp.5128 - 5148. ** R u mo r e , M . M . and Vogenbe r g , F . R . , 2016. Bio s imila rs : st ill no t qu i t e r ead y fo r pr ime t ime . Pha r mac y and The r a p e ut ic s , 41 ( 6 ), p.366. GELTEQ CAN ADRESSES KEY CHALLENGES PHARMACEUTICAL & SUPPLEMENT COMPANIES ARE FACING

GELTEQ MARKETS © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q ’ s p la t fo r m i s able t o w o r k ac r o ss t he belo w v e rt ical s. We offe r a com p le t e end - t o - end s e rv ice fo r o ur licen s ed p a rt ne rs. HUMAN HEALTH H u man Pha r mace ut ical H u man N utr ace ut ical ANIMAL HEALTH Animal Pha r mace ut ical Animal N utr ace ut ical

2024 2030 0 500 1000 1500 2000 2024 2034 0 500 1000 1500 2000 MARKET OPPORTUNITY ( HUMAN HEALTH ) The global p ha r mace ut ical ma r ke t Global n utr ace ut ical / supp lemen t ma r ke t $ 1 , 645.7 B $ 591.1 B 6.12 % CAGR 7.6 % CAGR $ 2 , 350.4 B $ 919.1 B So ur ce: G r and Vie w Re s ea r ch . ( 2025 ) . N utr ace ut ical s ma r ke t s i z e, s ha r e & tr end s anal ys i s r e p o rt , 2025 - 2030. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. So ur ce: G r and Vie w Re s ea r ch . ( 2025 ) . Pha r mace ut ical Ma r ke t ( 2025 - 2030 ) .

2024 2035 35 30 25 20 15 10 5 0 MARKET OPPORTUNITY ( ANIMAL HEALTH ) Global p e t p ha r mace ut ical ma r ke t $ 13.2B 7.85% CAGR $ 30.3B Gelteq makes supplement and medication delivery simple and stress - free for pets , pet owners , and veterinarians alike. 2023 2030 © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. 35 30 25 20 15 10 5 0 Global p e t n utr ace ut ical / supp lemen t ma r ke t $ 6.8 B 6.4% CAGR $ 10.5 B So ur ce: G r and Vie w Re s ea r ch . ( 2023 ) . Global p e t n utr ace ut ical s ma r ke t s i z e & o ut look, 2023 - 2030. So ur ce: Me t a t ech In s igh ts. ( 2024 ) . Pe t Pha r mace ut ical s ma r ke t s i z e, s ha r e & fo r eca st 2025 - 2035 (Re p o rt ID: MI 1173 )

O ur str a t eg y i s t o p a rt ne r w i t h p ha r mace ut ical and supp lemen t com p anie s t o de v elo p ʁ man u fac tur e ʁ and licen s e gel ʉ ba s ed pr od u c ts. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. GELTEQ B 2 B STRATEGY We a r e c urr en t l y foc us ed on demon str a t ing t he ca p abili t ie s of o ur d ru g deli v e ry p la t fo r m t o pr o sp ec t i v e p ha r mace ut ical com p anie s w ho can licen s e o ur t echnolog y fo r ne w pr od u c t s ale s Pha r mace ut ical Com p anie s S upp lemen t / N utr ace ut ical Com p anie s We a r e ac t i v el y engaging w i t h n utr ace ut ical ʤ supp lemen t com p anie s t o licen s e pr od u c ts f r om o ur p o rt folio of gel pr od u c ts. We al s o de v elo p c ust om gel fo r m u la t ion s t ailo r ed t o sp ecific need s.

RESEARCH & DEVELOPMENT PIPELINE SNAPSHOT © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Pain Managemen t Alle r g y Diabe t e s Weigh t Managemen t Medicinal Cannabi s Men t al Heal t h Refl ux ( GERD ) An t i p a r a s i t ic Ve t e r ina r ian Oncolog y GeRX - 761 GeRX - 561 GeRX - 461 GeR x - 481 GeR x - 081 GeRX - 261 GeRX - 681 GeRx - 941 GeRX - 341 H u man Animal Di s co v e ry P r e Clinical Clinical Reg u la t o ry A ppr o v ed O pt imi s a t ion

Da rr o w A ss ocia t e s Ma tt K r e ps Managing Di r ec t o r A ust in, Te x a s Uni t ed S t a t e s T: 214 - 597 - 8200 mk r e ps @ da rr o w i r. com In v e st o r Rela t ion s Gel t e q Na t han Gi v oni, CEO Mona s h Inno v a t ion Lab s G .60 , 22 Alliance Lane Cla yt on 3800 Vic t o r ia A ustr alia T: + 61 3 9087 3990 i r @gel t e q. com h ttps :// www. gel t e q. com Com p an y © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.